How Will Nuvation Bio Inc. (NYSE: NUVB) Look After It Drops -272.37% From Its Highs? – Marketing Sentinel
Home  »  Business   »  How Will Nuvation Bio Inc. (NYSE: NUVB) Look After...

How Will Nuvation Bio Inc. (NYSE: NUVB) Look After It Drops -272.37% From Its Highs?

During the last session, Nuvation Bio Inc. (NYSE:NUVB)’s traded shares were 0.58 million. At the end of the trading day, the stock’s price was $4.09, reflecting an intraday gain of 4.34% or $0.17. The 52-week high for the NUVB share is $15.23, that puts it down -272.37 from that peak though still a striking 12.22% gain since the share price plummeted to a 52-week low of $3.59. The company’s market capitalization is $943.60M, and the average trade volume was 912.85K shares over the past three months.

Nuvation Bio Inc. (NUVB) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. NUVB has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.12.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Nuvation Bio Inc. (NYSE:NUVB) trade information

Nuvation Bio Inc. (NUVB) registered a 4.34% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.34% in intraday trading to $4.09 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -9.31%, and it has moved by -25.09% in 30 days. Based on these gigs, the overall price performance for the year is -62.89%.

The consensus price target of analysts on Wall Street is $14.67, which implies an increase of 72.12% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $17.00 respectively. As a result, NUVB is trading at a discount of -315.65% off the target high and -193.4% off the low.

Nuvation Bio Inc. (NUVB) estimates and forecasts

Statistics show that Nuvation Bio Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Nuvation Bio Inc. (NUVB) shares have gone down -55.05% during the last six months, with a year-to-date growth rate less than the industry average at -29.55% against -0.10.

While earnings are projected to return -48.60% in 2022.

NUVB Dividends

Nuvation Bio Inc. is due to release its next quarterly earnings between March 09 and March 14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Nuvation Bio Inc. (NYSE:NUVB)’s Major holders

Nuvation Bio Inc. insiders own 27.16% of total outstanding shares while institutional holders control 67.35%, with the float percentage being 92.46%. FMR, LLC is the largest shareholder of the company, while 147 institutions own stock in it. As of Sep 29, 2021, the company held over 32.13 million shares (or 14.75% of all shares), a total value of $319.37 million in shares.

The next largest institutional holding, with 28.21 million shares, is of Omega Fund Management, Llc’s that is approximately 12.95% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $280.43 million.

Also, the Mutual Funds coming in first place with the largest holdings of Nuvation Bio Inc. (NUVB) shares are Fidelity Contrafund Inc and Vanguard Total Stock Market Index Fund. Data provided on Oct 30, 2021 indicates that Fidelity Contrafund Inc owns about 6.91 million shares. This amounts to just over 3.17 percent of the company’s overall shares, with a $63.37 million market value. The same data shows that the other fund manager holds slightly less at 3.99 million, or about 1.83% of the stock, which is worth about $39.63 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts